Search Results - "Aung, K.L."

Prognosis of familial pancreatic cancer (FPC): A matched case analysis by O'Kane, G.M., Borgida, A., Dodd, A., Aung, K.L., Holter, S., Knox, J., Gallinger, S.

Get full text

615P - Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC) by Alshammari, K., Aung, K.L., Zhang, T., Albiruni, A.R.R., Serra, S., Stockley, T., Wang, L., Nguyen, J., Spreafico, A., Hansen, A.R., Zwir, D., Siu, L.L., Bedard, P.

“…MEK inhibition may overcome resistance to EGFR inhibition alone in patients (pts) with RAS wt mCRC. We evaluated the antitumor activity of T (MEK1/2 inhibitor)…”
Get full text

Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC) by Alshammari, K., Aung, K.L., Zhang, T., Albiruni, A.R.R., Serra, S., Stockley, T., Wang, L., Nguyen, J., Spreafico, A., Hansen, A.R., Zwir, D., Siu, L.L., Bedard, P.

Get full text

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study by Mehnert, J.M., Rugo, H.S., O'Neil, B.H., Santoro, A., Schellens, J.H.M., Cohen, R.B., Doi, T., Ott, P.A., Pishvaian, M.J., Puzanov, I., Aung, K.L., Hsu, C., Le Tourneau, C., Soria, J-C., Elez, E., Tamura, K., Gould, M., Zhao, G., Stein, K., Piha-Paul, S.A.

Get full text